Literature DB >> 23151846

miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes.

Chonglin Luo1, Paul W Tetteh2, Patrick R Merz2, Elke Dickes2, Alia Abukiwan2, Agnes Hotz-Wagenblatt3, Stefan Holland-Cunz4, Tobias Sinnberg5, Birgit Schittek5, Dirk Schadendorf6, Sven Diederichs7, Stefan B Eichmüller8.   

Abstract

MicroRNAs are small noncoding RNAs that regulate gene expression and have important roles in various types of cancer. Previously, miR-137 was reported to act as a tumor suppressor in different cancers, including malignant melanoma. In this study, we show that low miR-137 expression is correlated with poor survival in stage IV melanoma patients. We identified and validated two genes (c-Met and YB1) as direct targets of miR-137 and confirmed two previously known targets, namely enhancer of zeste homolog 2 (EZH2) and microphthalmia-associated transcription factor (MITF). Functional studies showed that miR-137 suppressed melanoma cell invasion through the downregulation of multiple target genes. The decreased invasion caused by miR-137 overexpression could be phenocopied by small interfering RNA knockdown of EZH2, c-Met, or Y box-binding protein 1 (YB1). Furthermore, miR-137 inhibited melanoma cell migration and proliferation. Finally, miR-137 induced apoptosis in melanoma cell lines and decreased BCL2 levels. In summary, our study confirms that miR-137 acts as a tumor suppressor in malignant melanoma and reveals that miR-137 regulates multiple targets including c-Met, YB1, EZH2, and MITF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151846     DOI: 10.1038/jid.2012.357

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  62 in total

1.  The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.

Authors:  Matthew L Fisher; Gautam Adhikary; Dan Grun; David M Kaetzel; Richard L Eckert
Journal:  Mol Carcinog       Date:  2015-12-23       Impact factor: 4.784

Review 2.  Pivotal MicroRNAs in Melanoma: A Mini-Review.

Authors:  Zhenjun Deng; Jingang Hao; Dongyun Lei; Yongjing He; Lechun Lu; Li He
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

3.  Prognostic role of YB-1 expression in breast cancer: a meta-analysis.

Authors:  Xu Wang; Xiao-Bo Guo; Xiao-Chun Shen; Hao Zhou; Dan-Wei Wan; Xiao-Feng Xue; Ye Han; Bin Yuan; Jin Zhou; Hong Zhao; Qiao-Ming Zhi; Yu-Ting Kuang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

Review 5.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

6.  Establishment of an miR-137-knockout cell model using CRISPR/Cas9 genome editing.

Authors:  Wei Chen; Qi Li; Jingjie Du; Xiaodi Li; Songshan Jiang; Yuanli He
Journal:  Oncol Lett       Date:  2018-07-06       Impact factor: 2.967

7.  MicroRNA-137 suppresses tongue squamous carcinoma cell proliferation, migration and invasion.

Authors:  Lanying Sun; Jin Liang; Qibao Wang; Zhaoyuan Li; Yi Du; Xin Xu
Journal:  Cell Prolif       Date:  2016-08-30       Impact factor: 6.831

Review 8.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

9.  Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.

Authors:  Po-Chen Chu; Peng-Chan Lin; Hsing-Yu Wu; Kuen-Tyng Lin; Christina Wu; Tanios Bekaii-Saab; Yih-Jyh Lin; Chung-Ta Lee; Jeng-Chang Lee; Ching-Shih Chen
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

Review 10.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.